Clinical Trial Update: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of AXS-05 in treatment-resistant major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Treatment Resistant Major Depressive Disorder | Phase 3 | Status: COMPLETED